The reported B‐ALL patients with JAK2 fusions often presented with hyperleukocytosis and responded unfavorably to chemotherapy with frequent relapse, and about one third of patients died from the disease during 33 months of follow‐up (Tirado et al., 2010). Here, JAK2 is linked to acute lymphoblastic leukemia.